NEW YORK (GenomeWeb) – CombiMatrix reported after the close of the market on Thursday a 28 percent jump in first quarter revenues, an increase driven by growing sales of both its microarray and non-microarray diagnostics tests.

For the three-month period ended March 31, CombiMatrix's revenues rose to $2.3 million from $1.8 million in the same period a year earlier, matching analysts' average estimate.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.